

Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please call 800-835-4709 or 240-402-8010, extension 1. CBER Consumer Affairs Branch or send an e-mail to: ocod@fda.hhs.gov and include 508 Accommodation and the title of the document in the subject line of your e-mail.



BIONTECH

2024-2025 COVID-19 Vaccine Formula: Pfizer/BioNTech Clinical and Preclinical Supportive Data

Vaccines and Related Biological
Products Advisory Committee

June 5, 2024

Presentation Outline



Kayvon Modjarrad, M.D., Ph.D.

Executive Director, Viral Vaccines & Immunology
Vaccine Research and Development, Pfizer Inc.


**Real-World Evidence &
Variant Epidemiology**

**Omicron XBB.1.5-Adapted Vaccine Clinical
Humoral Immune Responses**


**Preclinical Evaluation of
Omicron JN.1 Lineage-Adapted Vaccines**

Seasonal COVID-19 Burden is Comparable to or Higher than Influenza

U.S. Hospitalizations¹⁻³



U.S. Deaths²⁻⁴



* Error bars represent 95% uncertainty intervals for influenza and are not listed for COVID-19 data.

† 2020-2021 season estimates are not available due to minimal influenza activity.


1. US Department of Health & Human Services. COVID-19 Reported Patient Impact and Hospital Capacity by State Timeseries (RAW). https://healthdata.gov/Hospital/COVID-19-Reported-Patient-Impact-and-Hospital-Capa/g62h-syeh/about_data

2. Centers for Disease Control and Prevention. Disease Burden of Flu. <https://www.cdc.gov/flu/about/burden/index.html>.

3. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD). 2023-2024 U.S. Flu Season: Preliminary In-Season Burden Estimates. Accessed 2024 May 30. <https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm>.

4. Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2024 May 30. <https://covid.cdc.gov/covid-data-tracker>.

XBB.1.5 Vaccine Effectiveness Initially Robust, Decreased Over Course of 2023/2024 Season




VE, vaccine effectiveness

*Historical data from: <https://cov-spectrum.org>. Accessed 2024 March 14. † Includes outcomes such as symptomatic infections, outpatient visits, and infections that were almost all symptomatic.

Hansen CH et al. *Lancet Infect Dis* 2024;24:e73-4; van Werkhoven CH et al. *Euro Surveill* 2024;29:pii=2300703; Tartof SY et al. *medRxiv* 2024; DeCuir J et al. *MMWR* 2024;73:180-188; Huiberts AJ et al. *Euro Surveill* 2024;29:pii=2400109; Skowronski DM et al. *Euro Surveill* 2024;29:pii=2400076; Link-Gelles R et al. *MMWR* 2024;73:77-83 and updated at [ACIP](https://www.acip.gov)

Vaccine Effectiveness Lower Against JN.1 Compared to XBB, When Controlling for Time Since Vaccination



ARI, acute respiratory infection; CA, California; CI, confidence interval; No., number; PCR, polymerase chain reaction; VE, vaccine effectiveness

* Compared to no receipt of any XBB vaccine.


† Strain predominance periods defined as >80% prevalence of sequenced strains in the United States. The XBB period was defined as Sep 25 – Nov 30, 2023, and the JN.1 period was defined as Jan 1 – Jan 31, 2024.

‡ Strain determined using a hierarchical approach depending on available information: (i) whole genome sequencing (WGS), (ii) spike gene target failure, or (iii) periods of >80% sublineage predominance based on WGS data from US Health and Human Services Region 9. For (iii), cases were classified as XBB from Oct 10 – Dec 9, 2023, and as JN.1 from Jan 20 – Feb 29, 2024.


1. Caffrey et al. medRxiv. <https://www.medrxiv.org/content/10.1101/2024.04.05.24305063v1> 2. Tartof et al. medRxiv. <https://www.medrxiv.org/content/10.1101/2024.05.04.24306875v1>

XBB.1.5 Dominance Declining and XBB.1.16 Peaking at Time of June 2023 VRBPAC

Trajectory of Emerging Variants Compared with Historic Dominant Variants



JN.1 Transitioning to Rise of Expanding Set of Closely Related Sublineages






XBB.1.5 Omicron-Adapted Vaccine Clinical Humoral Immune Response

Clinical Study: XBB.1.5 Vaccine Neutralizing Titers Maintain Against Variant Drift Until Emergence of Omicron JN.1

Evaluable Immunogenicity Population* – FFRNT Assay



All participants were 18-55 years old; baseline seropositive for prior SARS-CoV-2 infection and had ≥ 3 mRNA COVID-19 vaccines with last vaccine being a bivalent (Original + Omicron BA.4/5) COVID-19 vaccine 150-365 days prior to enrolment.



GMFR = Geometric Mean Neutralizing Titer Fold Rise; Pre = Pre vaccination; 1MPD = 1 month post dose; FFRNT = fluorescent focus reduction neutralization test

XBB.1.5, BA.2.86 and EG.5.1 assays (grey, blue and purple bars) were run at a different time to JN.1 (green bars), which was also run with XBB.1.5, BA.2.86 (Neutralization titers and GMFRs were similar to those presented here).



Preclinical Evaluation of an Omicron JN.1 Adapted Vaccine

Vaccine-Experienced: 1 Month Post 5th Dose Neutralizing Responses Elicited by JN.1 and XBB.1.5 Vaccines



Pseudovirus neutralization assay; LOD = Limit of detection; the lowest serum dilution of 1:20.

N = 10 mice per vaccine group. Vaccine dose 0.5 µg.


"FLiRT" contains S: F456L, R346T; "deFLiRT" contains S: S31del, F456L, R346T; "FluQE" contains S: F456L, Q493E

Vaccine-Experienced: Geometric Mean Ratios of JN.1 to XBB.1.5 Vaccine Neutralizing Titers at 1 Month Post 5th Dose



Legend for neutralizing titers:

- JN.1
- JN.1.7
- KP.1.1
- JN.1.16.1
- KP.2
- KP.2.2
- KP.2.3
- LB.1
- KP.3





Pseudovirus neutralization assay.

N = 10 mice per vaccine group. Vaccine dose 0.5 µg.

"FLiRT" contains S: F456L, R346T; "deFLiRT" contains S: S31del, F456L, R346T; "FluQE" contains S: F456L, Q493E


Vaccine Naïve: 1 Month Post 2nd Dose Neutralizing Responses Elicited by JN.1 and XBB.1.5 Vaccines



Pseudovirus neutralization assay; LOD = Limit of detection; the lowest serum dilution of 1:20.



N = 10 mice per vaccine group. Vaccine dose 0.5 µg.

“FLiRT” contains S: F456L, R346T; “deFLiRT” contains S: S31del, F456L, R346T; “FluQE” contains S: F456L, Q493E




Preclinical Evaluation of an Omicron KP.2-Adapted Vaccine

Vaccine-Experienced: 2 Weeks Post 4th Dose Neutralizing Responses Elicited by XBB.1.5, JN.1 and KP.2 Vaccines




Pseudovirus neutralization assay; LOD = Limit of detection; the lowest serum dilution of 1:20.
 N = 10 mice per vaccine group. Vaccine dose 0.5 µg
 "FLiRT" = S: F456L, R346T; "deFLiRT" = S: S31del, F456L, R346T; "FluQE" = S: F456L, Q493E

Vaccine-Experienced: Geometric Mean Ratio of JN.1 and KP.2 Vaccine Responses Compared to XBB.1.5 Vaccine Responses, 2 Weeks Post 4th Dose



Legend: JN.1, JN.1.7, KP.1.1, JN.1.16.1, KP.2, KP.2.2, KP.2.3, LB.1, KP.3



Pseudovirus neutralization assay; LOD = Limit of detection; the lowest serum dilution of 1:20.
 N = 10 mice per vaccine group. Vaccine dose 0.5 µg
 "FLiRT" = S: F456L, R346T; "deFLiRT" = S: S31del, F456L, R346T; "FluQE" = S: F456L, Q493E

Conclusions

Summary Evidence Supports a JN.1 Lineage Vaccine Update for the 2024/2025 Season

- **XBB.1.5 vaccine had robust effectiveness against XBB lineages that declined against JN.1**
- **JN.1 sublineages are dominant, with minimal antigenic differences within family, mirroring observations for XBB lineages relative to XBB.1.5**
- **JN.1- and KP.2-adapted vaccines confer improved neutralizing responses over XBB.1.5 vaccine against broad panel of emerging variants**
- **Prepared to initiate supply of either JN.1 vaccine or KP.2 vaccine immediately upon approval**



2024-2025 COVID-19 Vaccine Formula: Pfizer/BioNTech Preclinical Supportive Data

Vaccines and Related Biological
Products Advisory Committee

June 5, 2024